PTPN11 and lymphoma: Interestingly, dual inhibition of SHP2 and ALK has been shown to be an effective approach for ALK-translocated lung tumors and lymphomas that are resistant to ALK inhibitors (33–35), suggesting potential benefits of combining ALK and SHP2 inhibitors.